97 related articles for article (PubMed ID: 25092113)
21. G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
Lesage S; Ibanez P; Lohmann E; Pollak P; Tison F; Tazir M; Leutenegger AL; Guimaraes J; Bonnet AM; Agid Y; Dürr A; Brice A;
Ann Neurol; 2005 Nov; 58(5):784-7. PubMed ID: 16240353
[TBL] [Abstract][Full Text] [Related]
22. Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Leder S; Weber Y; Altafaj X; Estivill X; Joost HG; Becker W
Biochem Biophys Res Commun; 1999 Jan; 254(2):474-9. PubMed ID: 9918863
[TBL] [Abstract][Full Text] [Related]
23. A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Dierssen M
Exp Neurol; 2013 Sep; 247():110-2. PubMed ID: 23570900
[No Abstract] [Full Text] [Related]
24. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
[TBL] [Abstract][Full Text] [Related]
25. Gene mutation linked to primary pulmonary hypertension.
Cockey CD
AWHONN Lifelines; 2000; 4(5):17-8. PubMed ID: 11898153
[No Abstract] [Full Text] [Related]
26. The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
Song LN; Silva J; Koller A; Rosenthal A; Chen EI; Gelmann EP
Mol Cancer Res; 2015 May; 13(5):913-22. PubMed ID: 25777618
[TBL] [Abstract][Full Text] [Related]
27. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
[TBL] [Abstract][Full Text] [Related]
28. A Korean Parkinson's disease family with the LRRK2 p.Tyr1699Cys mutation showing clinical heterogeneity.
Kim JS; Cho JW; Shin H; Lee WY; Ki CS; Cho AR; Kim HT
Mov Disord; 2012 Feb; 27(2):320-4. PubMed ID: 22162019
[TBL] [Abstract][Full Text] [Related]
29. Down syndrome--new prospects for an ancient disorder.
Einfeld SL; Brown R
JAMA; 2010 Jun; 303(24):2525-6. PubMed ID: 20571021
[No Abstract] [Full Text] [Related]
30. Antagonism of Chk1 signaling in the G2 DNA damage checkpoint by dominant alleles of Cdr1.
Calonge TM; O'Connell MJ
Genetics; 2006 Sep; 174(1):113-23. PubMed ID: 16816416
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis: A clear answer.
Sohn E
Nature; 2016 Sep; 537(7619):S64-5. PubMed ID: 27602744
[No Abstract] [Full Text] [Related]
32. All for one and one for all.
Greaves S
Nat Cell Biol; 2001 Aug; 3(8):E184. PubMed ID: 11483975
[No Abstract] [Full Text] [Related]
33. Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants.
Ewton DZ; Lee K; Deng X; Lim S; Friedman E
Int J Cancer; 2003 Jan; 103(1):21-8. PubMed ID: 12455049
[TBL] [Abstract][Full Text] [Related]
34. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of dual specificity kinase activity of DYRK1A.
Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
[TBL] [Abstract][Full Text] [Related]
36. Letter concerning: 'Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo'.
da Costa Martins PA; De Windt LJ
Cardiovasc Res; 2011 Sep; 91(4):742-3; author reply 743-4. PubMed ID: 21795320
[No Abstract] [Full Text] [Related]
37. Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence.
Zhou N; Yuan S; Wang R; Zhang W; Chen JJ
Oncotarget; 2015 Oct; 6(31):30745-61. PubMed ID: 26307683
[TBL] [Abstract][Full Text] [Related]
38. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
Nichols WC; Pankratz N; Hernandez D; Paisán-Ruíz C; Jain S; Halter CA; Michaels VE; Reed T; Rudolph A; Shults CW; Singleton A; Foroud T;
Lancet; 2005 Jan 29-Feb 4; 365(9457):410-2. PubMed ID: 15680455
[TBL] [Abstract][Full Text] [Related]
39. Lrrk2 in the limelight!
Farrer MJ
Neurology; 2007 Oct; 69(18):1732-3. PubMed ID: 17967990
[No Abstract] [Full Text] [Related]
40. Peutz-Jeghers syndrome: genetic screening.
Leggett BA; Young JP; Barker M
Expert Rev Anticancer Ther; 2003 Aug; 3(4):518-24. PubMed ID: 12934663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
